SPHS - Sophiris Bio, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Sophiris Bio, Inc.

1258 Prospect Street
La Jolla, CA 92037
United States
858-777-1760
http://www.sophirisbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Mr. Randall E. WoodsCEO, Pres & Director537.28kN/A1952
Mr. Peter T. SloverChief Financial Officer358.31kN/A1975
Dr. Allison J. HulmeCOO, Head of R&D and Director529.73kN/A1963
Dr. Samuel R. DenmeadeChief Scientific Officer & Member of the Scientific Advisory BoardN/AN/AN/A
Dr. James Joseph Beesley BSc,DCSr. Director of Investor RelationsN/AN/A1972
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Corporate Governance

Sophiris Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.